{"product_id":"insulin-resistance-insulin-action-and-its-disturbances-in-disease-hardback-9780470850084","title":"Insulin Resistance; Insulin Action and its Disturbances in Disease (Hardback) 9780470850084","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eInsulin Resistance\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eInsulin Action and its Disturbances in Disease\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eSudhesh Kumar (Edited by), S Kumar (Author), Stephen O'Rahilly (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470850084, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 19 November 2004\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e624 pages\u003cbr\u003e24.6 x 17.5 x 3.6 cm, 1.191 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"The book is intended for specialists…however with the current interest in obesity and the threats it poses to the general public health, others will also find it of interest.\" (\u003ci\u003eE-STREAMS\u003c\/i\u003e, September 2006)  \u003cp\u003e\"...a major contribution to the increasing body of work...this book appears at an appropriate moment to educate and excite young investigators…\" (\u003ci\u003eNew England Journal of Medicine\u003c\/i\u003e, November 17, 2005)\u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eDiabetes is now one of the major causes of morbidity worldwide. In many cases, the onset of diabetes is progressive, developing via a condition of insulin resistance. This book considers the development of this condition, its consequences and clinical and therapeutic aspects.\u003cbr\u003e \u003cbr\u003e The book reviews the normal biology of insulin action on glucose, lipids and proteins. It considers the pathological basis for insulin resistance in animal models and humans, and discusses the influence of heredity, dietary factors and exercise. Clinical consequences including dyslipidaemia, hypertension and polycystic ovary syndrome, and therapeutic strategies for treatment are also examined.\u003cbr\u003e * Provides an expert review of the phenomenon of insulin resistance\u003cbr\u003e * Brings together a host of recent research for the first time\u003cbr\u003e * Written by leading experts in biological and clinical research\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eList of Contributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Insulin Receptor and Downstream Signalling 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKen Siddle\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 Insulin receptor structure and function 2\u003c\/p\u003e \u003cp\u003e1.3 Insulin receptor substrates 15\u003c\/p\u003e \u003cp\u003e1.4 Downstream signalling pathways 23\u003c\/p\u003e \u003cp\u003e1.5 The basis of insulin’s signalling specificity 37\u003c\/p\u003e \u003cp\u003e1.6 Conclusion 38\u003c\/p\u003e \u003cp\u003eReferences 39\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Insulin-mediated Regulation of Glucose Metabolism 63\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDaniel Konrad, Assaf Rudich and Amira Klip\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 63\u003c\/p\u003e \u003cp\u003e2.2 Insulin as a master regulator of whole body glucose disposal 63\u003c\/p\u003e \u003cp\u003e2.3 Insulin-mediated regulation of glucose metabolic pathways 67\u003c\/p\u003e \u003cp\u003e2.4 Glucose uptake into skeletal muscle – the rate-limiting step in glucose metabolism 69\u003c\/p\u003e \u003cp\u003eAcknowledgements 78\u003c\/p\u003e \u003cp\u003eReferences 78\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Insulin Action on Lipid Metabolism 87\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eKeith N. Frayn and Fredrik Karpe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction: does insulin affect lipid metabolism? 87\u003c\/p\u003e \u003cp\u003e3.2 Molecular mechanisms by which insulin regulates lipid metabolism 88\u003c\/p\u003e \u003cp\u003e3.3 Insulin and lipolysis 89\u003c\/p\u003e \u003cp\u003e3.4 Insulin, lipoprotein lipase and cellular fatty acid uptake 94\u003c\/p\u003e \u003cp\u003e3.5 Co-ordinated regulation of fatty acid synthesis and ketogenesis 96\u003c\/p\u003e \u003cp\u003e3.6 Insulin and cholesterol synthesis 97\u003c\/p\u003e \u003cp\u003e3.7 Insulin effects on lipoprotein metabolism 98\u003c\/p\u003e \u003cp\u003eAcknowledgement 99\u003c\/p\u003e \u003cp\u003eReferences 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The Effect of Insulin on Protein Metabolism 105\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eLaura J. S. Greenlund and K. Sreekumaran Nair\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 105\u003c\/p\u003e \u003cp\u003e4.2 Molecular mechanisms of insulin’s effect on protein turnover 107\u003c\/p\u003e \u003cp\u003e4.3 Measurement of protein metabolism (synthesis and breakdown or turnover) in human subjects 111\u003c\/p\u003e \u003cp\u003e4.4 Whole body and regional protein turnover 114\u003c\/p\u003e \u003cp\u003eAcknowledgements 125\u003c\/p\u003e \u003cp\u003eReferences 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Genetically Modified Mouse Models of Insulin Resistance 133\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGema Medina-Gomez, Christopher Lelliott and Antonio J. Vidal-Puig\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 133\u003c\/p\u003e \u003cp\u003e5.2 Genetic modification as a tool to dissect the mechanisms leading to insulin resistance 134\u003c\/p\u003e \u003cp\u003e5.3 Candidate genes involved in the mechanisms of insulin resistance 134\u003c\/p\u003e \u003cp\u003e5.4 Insulin signalling network 136\u003c\/p\u003e \u003cp\u003e5.5 Factors leading to insulin resistance 137\u003c\/p\u003e \u003cp\u003e5.6 Defining the function of the insulin cascade molecules through global knockouts 137\u003c\/p\u003e \u003cp\u003e5.7 Double heterozygous mice as models of polygenic forms of diabetes 139\u003c\/p\u003e \u003cp\u003e5.8 Defining tissue and\/or organ relevance for the maintenance of insulin sensitivity 140\u003c\/p\u003e \u003cp\u003e5.9 Genetically modified mice to study modulators of insulin sensitivity 142\u003c\/p\u003e \u003cp\u003e5.10 Lipodystrophy versus obesity, the insulin resistance paradox 143\u003c\/p\u003e \u003cp\u003e5.11 Excess of nutrients as a cause of insulin resistance 147\u003c\/p\u003e \u003cp\u003e5.12 PPARs, key mediators of nutritional-regulated gene expression and insulin sensitivity 148\u003c\/p\u003e \u003cp\u003eReferences 148\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Insulin Resistance in Glucose Disposal and Production in Man with Specific Reference to Metabolic Syndrome and Type 2 Diabetes 155\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHenning Beck-Nielsen, Frank Alford and Ole Hother-Nielsen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 155\u003c\/p\u003e \u003cp\u003e6.2 Measurement of insulin resistance 157\u003c\/p\u003e \u003cp\u003e6.3 Insulin-resistant states 162\u003c\/p\u003e \u003cp\u003e6.4 Conclusion and perspectives 171\u003c\/p\u003e \u003cp\u003eReferences 172\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Central Regulation of Peripheral Glucose Metabolism 179\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStanley M. Hileman and Christian Bjørbæk\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 179\u003c\/p\u003e \u003cp\u003e7.2 Counter-regulation of hypoglycaemia – role of the CNS 180\u003c\/p\u003e \u003cp\u003e7.3 Brain regions involved in counter-regulation 182\u003c\/p\u003e \u003cp\u003e7.4 Glucosensing neurons 184\u003c\/p\u003e \u003cp\u003e7.5 Central control of peripheral organs involved in glucoregulation 187\u003c\/p\u003e \u003cp\u003e7.6 Additional afferent signals to the CNS regulating peripheral glucose metabolism 189\u003c\/p\u003e \u003cp\u003e7.7 Conclusions and future perspectives 194\u003c\/p\u003e \u003cp\u003eAcknowledgements 196\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Relationship between Fat Distribution and Insulin Resistance 207\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePhilip G. McTernan, Aresh Anwar and Sudhesh Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 207\u003c\/p\u003e \u003cp\u003e8.2 Fat and its distribution 207\u003c\/p\u003e \u003cp\u003e8.3 Basis for variation in adipose tissue mass 209\u003c\/p\u003e \u003cp\u003e8.4 Change in adipocyte phenotype with obesity 210\u003c\/p\u003e \u003cp\u003e8.5 Obesity and its association with insulin resistance 210\u003c\/p\u003e \u003cp\u003e8.6 Subcutaneous and visceral adipose tissue 211\u003c\/p\u003e \u003cp\u003e8.7 The pathogenic significance of abdominal adipose tissue 211\u003c\/p\u003e \u003cp\u003e8.8 Potential mechanisms linking central obesity to the metabolic syndrome 212\u003c\/p\u003e \u003cp\u003e8.9 Randle hypothesis\/glucose–fatty acid hypothesis 212\u003c\/p\u003e \u003cp\u003e8.10 Alternatives to the Randle hypothesis 213\u003c\/p\u003e \u003cp\u003e8.11 Ectopic fat storage: fat content in obesity 214\u003c\/p\u003e \u003cp\u003e8.12 Adipose tissue as an endocrine organ 214\u003c\/p\u003e \u003cp\u003e8.13 Plasminogen activator–inhibitor 1 215\u003c\/p\u003e \u003cp\u003e8.14 Renin angiotensin system in adipose tissue 216\u003c\/p\u003e \u003cp\u003e8.15 Visceral obesity and steroid hormone metabolism 217\u003c\/p\u003e \u003cp\u003e8.16 Glucocorticoid metabolism and obesity 217\u003c\/p\u003e \u003cp\u003e8.17 11β-hydroxysteroid dehydrogenase (11β-HSD) 218\u003c\/p\u003e \u003cp\u003e8.18 Isoenzymes of 11β-HSD 218\u003c\/p\u003e \u003cp\u003e8.19 11β-HSD and obesity 219\u003c\/p\u003e \u003cp\u003e8.20 Sex steroid metabolism and obesity: oestrogen biosynthesis 220\u003c\/p\u003e \u003cp\u003e8.21 Aromatase 220\u003c\/p\u003e \u003cp\u003e8.22 Sex steroids and body fat 222\u003c\/p\u003e \u003cp\u003e8.23 Summary 224\u003c\/p\u003e \u003cp\u003eAcknowledgement 224\u003c\/p\u003e \u003cp\u003eReferences 224\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 PPARγ and Glucose Homeostasis 237\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRobert K. Semple and Stephen O’Rahilly\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Evidence from cell and rodent models 238\u003c\/p\u003e \u003cp\u003e9.2 Insights from human studies 251\u003c\/p\u003e \u003cp\u003eReferences 256\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Adipokines and Insulin Resistance 269\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDaniel K. Clarke and Vidya Mohamed-Ali\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Obesity and insulin resistance 270\u003c\/p\u003e \u003cp\u003e10.2 Adipokines implicated in insulin resistance 272\u003c\/p\u003e \u003cp\u003e10.3 Conclusions 280\u003c\/p\u003e \u003cp\u003eReferences 280\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Dietary Factors and Insulin Resistance 297\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJeremy Krebs and Susan Jebb\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 297\u003c\/p\u003e \u003cp\u003e11.2 The importance of body fatness 298\u003c\/p\u003e \u003cp\u003e11.3 Specific dietary factors 302\u003c\/p\u003e \u003cp\u003e11.4 Summary 310\u003c\/p\u003e \u003cp\u003eReferences 311\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Physical Activity and Insulin Resistance 317\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNicholas J. Wareham, Søren Brage, Paul W. Franks and Rebecca A. Abbott\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 317\u003c\/p\u003e \u003cp\u003e12.2 Evidence from observational studies of the association between physical activity and insulin resistance 318\u003c\/p\u003e \u003cp\u003e12.3 Summary of findings from observational studies in adults 318\u003c\/p\u003e \u003cp\u003e12.4 Summary of findings from observational studies in children and adolescents 340\u003c\/p\u003e \u003cp\u003e12.5 Mechanisms underlying the association between physical activity and insulin resistance 351\u003c\/p\u003e \u003cp\u003e12.6 Trials of the effect of physical activity on insulin sensitivity in adults 353\u003c\/p\u003e \u003cp\u003e12.7 Trials of the effect of physical activity on insulin sensitivity in children and adolescents 374\u003c\/p\u003e \u003cp\u003e12.8 Evidence of heterogeneity of the effect of physical inactivity on insulin resistance in sub-groups of the population 375\u003c\/p\u003e \u003cp\u003e12.9 Conclusions 385\u003c\/p\u003e \u003cp\u003eReferences 386\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Genetics of the Metabolic Syndrome 401\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eGeorge Argyropoulos, Steven Smith and Claude Bouchard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Historical perspective 401\u003c\/p\u003e \u003cp\u003e13.2 Pathophysiology 404\u003c\/p\u003e \u003cp\u003e13.3 Genetic epidemiology 407\u003c\/p\u003e \u003cp\u003e13.4 Monogenic disorders 411\u003c\/p\u003e \u003cp\u003e13.5 Candidate genes 414\u003c\/p\u003e \u003cp\u003e13.6 Genomic scans 426\u003c\/p\u003e \u003cp\u003e13.7 Conclusions 427\u003c\/p\u003e \u003cp\u003eReferences 427\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Insulin Resistance and Dyslipidaemia 451\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBenoît Lamarche and Jean-François Mauger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 451\u003c\/p\u003e \u003cp\u003e14.2 Historical notes 451\u003c\/p\u003e \u003cp\u003e14.3 Obesity versus the insulin resistance syndrome 453\u003c\/p\u003e \u003cp\u003e14.4 Hypertriglyceridaemia 453\u003c\/p\u003e \u003cp\u003e14.5 Reduced HDL cholesterol concentrations 455\u003c\/p\u003e \u003cp\u003e14.6 Small, dense LDL particles 457\u003c\/p\u003e \u003cp\u003e14.7 LDL cholesterol levels versus LDL particle number 459\u003c\/p\u003e \u003cp\u003e14.8 Insulin resistance, dyslipidaemia and the risk of cardiovascular disease 460\u003c\/p\u003e \u003cp\u003e14.9 Conclusions 461\u003c\/p\u003e \u003cp\u003eReferences 461\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Insulin Resistance, Hypertension and Endothelial Dysfunction 467\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStephen J. Cleland and John M. C. Connell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 467\u003c\/p\u003e \u003cp\u003e15.2 Hyperinsulinaemia, insulin resistance and hypertension 467\u003c\/p\u003e \u003cp\u003e15.3 Possible mechanisms linking insulin with blood pressure 468\u003c\/p\u003e \u003cp\u003e15.4 Atherosclerosis and insulin resistance 469\u003c\/p\u003e \u003cp\u003e15.5 Vascular endothelial dysfunction and mechanisms of atherothrombotic disease 469\u003c\/p\u003e \u003cp\u003e15.6 Direct vascular action of insulin 471\u003c\/p\u003e \u003cp\u003e15.7 What causes abnormal insulin signalling in metabolic and vascular tissues? 474\u003c\/p\u003e \u003cp\u003e15.8 Summary and conclusions (Figure 15.8) 477\u003c\/p\u003e \u003cp\u003eReferences 478\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Insulin Resistance and Polycystic Ovary Syndrome 485\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNeus Potau\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 485\u003c\/p\u003e \u003cp\u003e16.2 Definition of polycystic ovary syndrome (PCOS) and diagnostic criteria 486\u003c\/p\u003e \u003cp\u003e16.3 Hyperandrogenism and hyperinsulinism 489\u003c\/p\u003e \u003cp\u003e16.4 Assessment of insulin resistance in PCOS 491\u003c\/p\u003e \u003cp\u003e16.5 Gene studies on PCOS 492\u003c\/p\u003e \u003cp\u003e16.6 Premature pubarche, hyperinsulinism and PCOS 495\u003c\/p\u003e \u003cp\u003e16.7 Treatment approach with antiandrogens 497\u003c\/p\u003e \u003cp\u003e16.8 Treatment approach with insulin sensitizers (metformin) 498\u003c\/p\u003e \u003cp\u003e16.9 Treatment approach with insulin sensitizers (thiazolidinediones) 501\u003c\/p\u003e \u003cp\u003e16.10 Conclusion 502\u003c\/p\u003e \u003cp\u003eReferences 502\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Syndromes of Severe Insulin Resistance (SSIRs) 511\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDavid Savage and Stephen O’Rahilly\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 511\u003c\/p\u003e \u003cp\u003e17.2 General biochemical and clinical features of severe insulin resistance 512\u003c\/p\u003e \u003cp\u003e17.3 Classification of specific syndromes of insulin resistance 514\u003c\/p\u003e \u003cp\u003e17.4 Primary disorders of insulin action 515\u003c\/p\u003e \u003cp\u003e17.5 Lipodystrophic syndromes and a lipocentric approach to diabetes 518\u003c\/p\u003e \u003cp\u003e17.6 Complex genetic syndromes associated with severe insulin resistance 525\u003c\/p\u003e \u003cp\u003e17.7 Therapeutic options in the syndromes of severe insulin resistance 526\u003c\/p\u003e \u003cp\u003eReferences 527\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Therapeutic Strategies for Insulin Resistance 535\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eHarpal S. Randeva, Margaret Clarke and Sudhesh Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 535\u003c\/p\u003e \u003cp\u003e18.2 Obesity and insulin resistance 535\u003c\/p\u003e \u003cp\u003e18.3 Management of obesity 537\u003c\/p\u003e \u003cp\u003e18.4 Dietary management of obesity 539\u003c\/p\u003e \u003cp\u003e18.5 Exercise and physical activity 540\u003c\/p\u003e \u003cp\u003e18.6 Anti-obesity drugs 540\u003c\/p\u003e \u003cp\u003e18.7 Surgical management of obesity 543\u003c\/p\u003e \u003cp\u003e18.8 Pharmacological treatment of insulin resistance 544\u003c\/p\u003e \u003cp\u003e18.9 Insulin sensitizers and cardiovascular risk factors 551\u003c\/p\u003e \u003cp\u003e18.10 Conclusions 553\u003c\/p\u003e \u003cp\u003eReferences 554\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Drug Therapy for Insulin Resistance – a Look at the Future 561\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBei B. Zhang and David E. Moller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 561\u003c\/p\u003e \u003cp\u003e19.2 Targeting molecules within the insulin signal transduction pathway 563\u003c\/p\u003e \u003cp\u003e19.3 Targeting negative modulators of insulin signalling 567\u003c\/p\u003e \u003cp\u003e19.4 Targeting obesity and insulin resistance 569\u003c\/p\u003e \u003cp\u003eReferences 575\u003c\/p\u003e \u003cp\u003eIndex 587\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Family \u0026amp; health [\u003ca title=\"See our other books on Family \u0026amp; health\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Family%20\u0026amp;%20health%20%5BVF%5D%22\"\u003eVF\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278037741848,"sku":"9780470850084","price":154.87,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470850084.jpg?v=1781457089","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/insulin-resistance-insulin-action-and-its-disturbances-in-disease-hardback-9780470850084","provider":"Freshly Printed Books","version":"1.0","type":"link"}